Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

October 26th 2022

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial

October 26th 2022

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

The Role of Adjuvant Therapy in Patients with NSCLC

October 26th 2022

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Using Liquid Biopsy for Molecular Testing in NSCLC

October 26th 2022

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

October 26th 2022

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.

Types of Tissue Next-Generation Sequencing Platforms in NSCLC

October 26th 2022

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Sintilimab Plus Chemotherapy Improves PFS in Pretreated, EGFR-Mutant NSCLC

October 25th 2022

Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

October 24th 2022

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Ivonescimab Gets Breakthrough Therapy Designation in China for EGFR+ Advanced NSCLC

October 21st 2022

The China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab for use in combination with chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in whom prior treatment with an EGFR TKI has failed.

Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC

October 21st 2022

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

October 21st 2022

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.

Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

October 20th 2022

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

October 19th 2022

Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

October 19th 2022

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy

October 19th 2022

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC

October 19th 2022

Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.

Average Turnaround Time for NSCLC Molecular Testing

October 19th 2022

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Best Practices for Accurate Tissue Genotyping in NSCLC

October 19th 2022

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Novel HER2-Targeted Therapies for NSCLC

October 17th 2022

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

October 17th 2022

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.